Announcement: FDA approval for Magventure TMS in treatment of OCD
Magventure has worked closely with brain researchers for well over 25 years, providing numerous TMS solutions to help advance the field of neuroscience – both basic and applied. Expanding the treatment options to include other indications than major depressive disorder, such as OCD, is one more important step towards helping more adult patients improve their mental health.
Optimind Clinic Inc is a proud partner and uses the Magventure Transcranial Magnetic Stimulator.
Position Paper: Coverage Guidance for TMS for OCD, 2021
From the paper:
“rTMS (dTMS) with the H7 coil was cleared in August of 2018 as an adjunctive treatment for adults with Obsessive Compulsive Disorder (OCD).
In its approval, The FDA noted 38% of patients receiving dTMS had at least a 30% reduction in the Yale-Brown Obsessive-Compulsive Scale (YBOCS) score, compared with 11% of patients who received sham treatment.
Post marketing analysis of 219 patients from 22 community sites demonstrated a response rate of 57.9% after 29 sessions, with improving response rates and response magnitudes with longer treatment durations, 50% at 31 days and 78% after 60 days.
Clinical sub analysis and electrophysiological studies suggest that the mechanism of action of dTMS for OCD is different from medications and CBT, and non-response to either is not a predictor of response to TMS.
Additionally, patients with comorbid OCD and MDD generally only needed treatment with H7/OCD protocol to treat both conditions.”
Transcranial magnetic stimulation in the treatment of obsessive–compulsive disorder: current perspectives